C3L-02958
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 74.26146475
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- BILE_ACID_METABOLISM+0.230
- KRAS_SIGNALING_DN+0.170
- ESTROGEN_RESPONSE_EARLY+0.110
- PROTEIN_SECRETION+0.080
- MYOGENESIS+0.070
- UV_RESPONSE_DN+0.070
- HEME_METABOLISM+0.060
- ANDROGEN_RESPONSE+0.050
- NOTCH_SIGNALING+0.040
- COAGULATION+0.030
Top 10 suppressed
- E2F_TARGETS-0.610
- G2M_CHECKPOINT-0.580
- MYC_TARGETS_V2-0.520
- MYC_TARGETS_V1-0.500
- TNFA_SIGNALING_VIA_NFKB-0.410
- DNA_REPAIR-0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
- MTORC1_SIGNALING-0.380
- INTERFERON_GAMMA_RESPONSE-0.370
- MITOTIC_SPINDLE-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-02950 | — | cohortA1 | 0.924 |
| 2 | C3L-00893 | — | cohortA1 | 0.918 |
| 3 | TCGA-69-7764-01A-11R-2170-07 | — | cohortA2 | 0.907 |
| 4 | BS_063ERW0R | pilocytic astrocytoma | — | 0.903 |
| 5 | TCGA-55-8616-01A-11R-2403-07 | — | cohortA1 | 0.901 |
| 6 | TCGA-HD-8224-01A-11R-2403-07 | — | — | 0.898 |
| 7 | C3N-02973 | — | cohortA1 | 0.896 |
| 8 | BS_273HKCT4 | DNET | — | 0.890 |
| 9 | b03ebc32.a177.44c7.8b02.fcd6560712f2 | — | cohortA1 | 0.889 |
| 10 | MDT-AP-0153 | Med | Medulloblastoma | 0.887 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| BILE_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.170 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.110 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.080 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.070 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.070 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.050 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.040 | Inavolisib | — uncovered |
| COAGULATION | 0.030 | Binimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.030 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.010 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |